Sherbrooke Park Advisers’s Gilead Sciences GILD Stock Holding History

Sherbrooke Park Advisers’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,415	Closed	-$1.27M	–	342
2025 Q3	$1.27M	Buy	11,415 +2,875	+34%	+$327K	0.59%	12
2025 Q2	$947K	Buy	8,540 +142	+2%	+$15.1K	0.41%	48
2025 Q1	$941K	Buy	+8,398	New	+$867K	0.44%	27
2024 Q3	–	Sell	-9,754	Closed	-$669K	–	1027
2024 Q2	$669K	Sell	9,754 -7,854	-45%	-$524K	0.12%	288
2024 Q1	$1.29M	Buy	+17,608	New	+$1.35M	0.25%	101
2023 Q4	–	Sell	-22,085	Closed	-$1.66M	–	555
2023 Q3	$1.66M	Buy	22,085 +12,626	+133%	+$971K	0.53%	30
2023 Q2	$729K	Buy	+9,459	New	+$754K	0.38%	84

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sherbrooke Park Advisers's GILD Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Gilead Sciences (GILD) in Q4 2025, closing a stake of 11,415 shares — an estimated $1.27M sold.

Sherbrooke Park Advisers first reported a position in GILD in Q2 2023 and held it in 7 quarters. The position peaked at $1.66M in Q3 2023. 2,216 funds tracked by Wall St. Rank hold GILD as of Q4 2025.

Sherbrooke Park Advisers reported no remaining Gilead Sciences position as of Q4 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 11,415 Gilead Sciences shares in Q4 2025, an estimated $1.27M.
Sherbrooke Park Advisers first reported a position in Gilead Sciences in Q2 2023 and held it in 7 quarters.
Sherbrooke Park Advisers's Gilead Sciences position peaked at $1.66M in Q3 2023.
2,216 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.